



[www.uenps2016.org](http://www.uenps2016.org)



# Maternal, Neonatal Health and Developmental Research Network SAMID (RD16/0021/0001)

Máximo Vento MD PhD  
National Coordinator RETICS RED SAMID  
Division of Neonatology  
University & Polytechnic Hospital la Fe  
(Valencia; Spain)

# Aims & Objectives

- Promote research throughout the ***perinatal period (pregnancy & fetal development), infancy and childhood***.
- Evaluate ***endogenous*** (genetic) and ***exogenous*** (environmental) factors that influence growth, development and health of the individual from fetal stage to the end of growth and development and influence upon adult age health status.

# Primary objective

To study conditions that occur in the perinatal period, infancy and adolescence and how they may influence adult health status from different perspectives:

- Etiopathogenic (mechanisms)
- Preventive
- Therapeutic
- Evolving (long-term consequences).

# Strategic objectives

1. To generate new high-quality and relevant social and health knowledge in a specific time frame of human life span.
2. To optimize human and technical research resources.
  - ✓ Incorporating young researchers
  - ✓ Stimulating multidisciplinary approach to problems
  - ✓ Enhancing financial support for multinational resources
3. To promote incorporation of new groups and research centers to the RETIC RED SAMID enhancing the quality and quantity of biomedical research in Spain.
4. To promote the incorporation of RETIC RED SAMID to European Obstetrics and Research Infrastructures to contribute to the establishment of an European Maternal and Pediatric Research Network.

# Tactical objectives

- To promote the figure of the **Pre-and-Post Doctoral Research Fellows** in the field of experimental and clinical Perinatology
- To **further involve Staff** neonatologists and obstetricians in clinical and basic research (protected time in referral centers)
- To establish **clinical and methodological synergies**
- To develop **animal models**
- To establish a **network of European centers** of excellence to launch multicenter clinical trials.

# Infrastructure

- **13 acknowledged** Research Groups
- 120 clinical and basic researchers
- 12 young investigators with full research contract
- 1 network manager
- Budget allocated to promote the network, meetings, scientist stages, publications, webpage, etc.

# Infrastructure

- HU La Fe (Valencia)
- HU La Paz (Madrid; 2)
- HU 12 de Octubre (Madrid)
- HU Gregorio Marañón (Madrid)
- HU Cruces (Barakaldo, Bilbao)
- Universidad de Granada
- Universidad de Murcia
- HU Marqués de Valdecilla (Santander)
- H del Mar (Barcelona)
- H Vall d'Hebrón (Barcelona)
- H S Joan de Deu (Barcelona)
- Universidad de Zaragoza




# Infrastructure

- Cooperation with related Health Research Institutes:
  - Ancillary Methodological Platforms (epidemiology, statistics, economy, legal, ethics, etc.)
  - Analytical Platform (“omics”; basic laboratory needs)
- Basic Scientists:
  - Biologists, Geneticists, Analytical Chemists  
Pharmacologists, Microbiologist, Pathologist, etc.
- Clinical staff
  - Obstetrics, Surgery, Radiology, Neonatology, Nutrition, Endocrinology, etc.



# Infrastructure

- **Associated Clinical Groups**
  - A total of 23 hospitals
  - Devoted to actively participate in clinical trial.
  - Adequate infrastructure to recruit eligible patients
  - Infrastructure to obtain, process, store and ship biological samples
  - Are endowed with special funding
  - Can constitute in the future an Acknowledge Research Group



# Web SAMID network: [www.redsamid.net](http://www.redsamid.net)



The screenshot shows the homepage of the SAMID network website. At the top, there is a header with the SAMID logo, navigation links for social media (Facebook, Twitter, LinkedIn), and a search bar. Below the header is a main navigation menu with categories like 'INICIO', 'QUIENES SOMOS', 'COMISIONES', 'GRUPOS DE INVESTIGACIÓN', 'PRODUCCIÓN', 'NOTICIAS Y EVENTOS', and 'CONTACTO'. A dropdown menu for 'QUIENES SOMOS' is open, showing sub-links: 'Presentación', 'Organización', 'Estructura organizativa', 'Memorias Anuales', 'Hospitales, Institutos y Fundaciones', 'Programa de Investigación y Formación', and 'Colaboraciones y Alianzas'. The main content area features a large image of a newborn baby with medical sensors on its chest, with the word 'SALUD' overlaid. Below the image, there is a paragraph describing the network's objectives. At the bottom, there are three small thumbnail images.

**RED SAMID RETICS**  
Red de Salud Materno Infantil y del Desarrollo

RETICS financiada por el PN I+D+I 2008-2011, ISCIII - Subdirección General de Evaluación y Fomento de la Investigación y el Fondo Europeo de Desarrollo Regional (FEDER), ref. RD12/0026.

**INICIO** **QUIENES SOMOS** **COMISIONES** **GRUPOS DE INVESTIGACIÓN** **PRODUCCIÓN** **NOTICIAS Y EVENTOS** **CONTACTO**

**Presentación**  
**Organización**  
**Estructura organizativa**  
**Memorias Anuales**  
**Hospitales, Institutos y Fundaciones**  
**Programa de Investigación y Formación**  
**Colaboraciones y Alianzas**

**SALUD**

Objetivo: El principal objetivo es estudiar los diferentes procesos patológicos, condiciones nutricionales y ambientales perinatales y postnatales abordando el estudio de factores de la prematuridad, la prevención y seguridad de los pacientes, los factores ambientales y etiopatogénicos, la nutrición y desarrollo infantil así como el fomento de la investigación en nuevos productos y procedimientos terapéuticos. También es su objetivo el estudio de las consecuencias a largo plazo y su relación con ciertas alteraciones de alta prevalencia en edades posteriores de la vida, como son las enfermedades neuropsiquiátricas, la obesidad y sus complicaciones.

[www.redsamid.net/es/quienes-somos/](http://www.redsamid.net/es/quienes-somos/)

# Research involvement of SAMID



Translational  
Research



Clinical  
Trials

# Program #1 accepted by the ISCIII

(Ministry of Economy, Industry, Competitiveness; Kingdom of Spain)

## STATEMENT OF THE PROGRAMME RETICS COORDINATOR

**RETIC Code**  
**RD16/0022/0001**

<b>Network (Thematic area):</b> MATERNAL, INFANT AND DEVELOPMENTAL HEALTH RESEARCH NETWORK	
<b>Programme Title:</b>	Interventions during pregnancy, neonatal period, and pediatric age for prevention and treatment of conditions influencing adult health.
<b>Programme Leader:</b>	MAXIMO VENTO TORRES
<b>Applicant institution:</b>	FUNDACION PARA LA INVESTIGACIÓN HOSPITAL LA FE
<b>Work institution:</b>	HOSPITAL UNIVERSITARIO Y POLITÉCNICO LA FE
<b>Requested budget:</b>	2.473.100,00 €

# Program #2 accepted by the ISCIII

(Ministry of Economy, Industry, Competitiveness; Kingdom of Spain)

## STATEMENT OF THE PROGRAMME RETICS COORDINATOR

Before submitting your application please read carefully the instructions provided on the last page, otherwise you will not be able to correctly upload this document.

**RETIC Code**

**RD16/0022/0015**

**Network (Thematic area):** MATERNAL, INFANT AND DEVELOPMENTAL HEALTH RESEARCH NETWORK

**Programme Title:** CARDIOVASCULAR RISK-RELATED PRENATAL FACTORS

**Programme Leader:** ELISA LLURBA OLIVÉ

**Applicant institution:** FUNDACIÓ INSTITUT DE RECERCA DE LA VALL D'HEBRON (VHIR)

**Work institution:** HOSPITAL UNIVERSITARIO DE LA VALL D'HEBRON

**Requested budget:** 2.070.750 Euros

# Program #1 accepted by the ISCIII

(Ministry of Economy, Industry, Competitiveness; Kingdom of Spain)

## **OBJECTIVE 1**

*To study biomarkers of Intrauterine Growth Retardation, preeclampsia and chorioamnionitis capable of predicting postnatal developmental disorders related to neurocognitive development and nutritional and metabolic status.*

## **OBJECTIVE 2**

*To study the efficacy of clinical indicators and biomarkers to early predicting neurocognitive and developmental outcomes and identify risk factors for neurologic sequelae in children after acute neurologic injuries, and to analyze the effectiveness of diagnostic methods and prevention strategies.*

## **OBJECTIVE 3**

*To study neonatal risk factors for adverse nutritional and metabolic outcomes and possible preventive nutritional strategies.*

## **OBJECTIVE 4**

*To study pre-and-postnatal environmental factors associated with neurologic, nutritional, and metabolic conditions in the perinatal and childhood periods.*



# Program #1 accepted by the ISCIII

(Ministry of Economy, Industry, Competitiveness; Kingdom of Spain)

## DESCRIPTION OF EACH WORKPACKAGE


WP N°	1	Start Date/Start Event		01/01/2017		End Date/End Event		31/12/2021
WP TITLE	PRENATAL RISK FACTORS FOR ABNORMAL NEONATAL AND LONGTERM OUTCOME							
PI Family Name	LLURBA	GOMEZ	VENTO	CABAÑAS	PALLAS	LOPEZ DE HEREDIA	GARCIA ALGAR	RODRIGUEZ
Group N°	5	4	1	2	3	6	7	10
N° of Resarchers	7	11	17	16	18	10	10	9

## OBJECTIVES

Max. 1,200 characters

- 1.1 To establish a protocol for the diagnosis and obstetrical management of conditions prompting preterm delivery including preeclampsia, IUGR, chorioamnionitis.
- 1.2 To study the interrelation between epidemiological, toxic, environmental, socio-economic variables and maternal risk factors leading to impairment of neurodevelopment.
- 1.3 To study the relationship between Doppler hemodynamic compromise of umbilical blood flow and alteration of neurodevelopment.
- 1.4 To study the interrelation between perinatal complications, postnatal adaptation and neurodevelopment.
- 1.5 To develop a fetal model of IUGR, to study factor affective fetal growth and test possible preventive and therapeutic strategies.





However the niche of opportunity for the promotion of clinical trials funded by International Institutions requires changes in logistic approach!

# Spanish Clinical Research Network (SCReN) Platform for Clinical Research and Trials





# Enpr-EMA

## Objective :

To facilitate studies in order to increase availability of medicinal products authorised for use in the paediatric population.

## Initiatives:

- ✓ fostering high-quality, ethical research on the quality, safety and efficacy of medicines for use in **children**
- ✓ helping with the recruitment of patients for clinical trials
- ✓ enabling collaboration between **networks and stakeholders**
- ✓ avoiding **unnecessary duplication** of studies
- ✓ building up **scientific and administrative competence** at a European level
- ✓ promoting **European Commission framework** programme applications.



innovative  
medicines  
initiative

# Innovative medicines initiative

- The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
- IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
- IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
- **IMI 2 - Call 6.**



**Pediatric Trials Network**



# Paediatric Trials Network


- The Paediatric Trials Network (PTN), sponsored by the National Institute of Child Health and Human Development (NICHD), is an alliance of clinical research sites cooperating in the design and conduct of paediatric clinical trials.
- PTN research provides evidence for optimal dosing of commonly used medications in infants and children, improving healthcare for these patients.

# Spanish Paediatric Clinical Trials Network (RECLIP)

## RECLIP Presentation Report

# Who we are


## a) national thematic networks




# Who we are:

## b) Current partners

### CURRENT PARTNERS OF RECLIP



# RECLIP SCIENTIFIC STRUCTURE



## Objectives of RECLIP

The **main objective of RECLIP** is to provide a fully developed and professionalized network of reference national clinical trial units, ensuring an appropriate infrastructure for conducting safe and effective paediatric clinical trials.

## HOW?

Through a **coordinated and super-specialized network** and a **professionalized, multidisciplinary and organized stable structure**, integrating the **most important paediatric clinical research units** across the country, located in the most important hospitals in Spain.

## WITH WHOM?

RECLIP develops its activity through the **cooperation with key stakeholders** inside and outside the network. The network joins strong and experienced national paediatric clinical and academic institutions with a long history of cross-collaboration with each other and the pharmaceutical industry.

## WHY?

The collaboration between reference entities in RECLIP allows to **reduce the uncertainty** and the risk inherent to the development of paediatric trials and **helps to accelerate** the process. All partners offer their expertise and best practices for the achievement of the aim of RECLIP.

Thanks for your attention!